Argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Argenx’s platforms allow the company to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect.
Argenx has made considerable progress since Foresite Capital's initial investment, with the advancement of several drug candidates into clinical development in both autoimmune and oncology indications. The company has expedited development on a novel drug candidate, Argx-113, which has the potential to treat certain autoimmune diseases. We believe this technology could be highly disruptive and displace the standard of care (plasma exchange and IV-Ig) for a variety of conditions involving pathogenic autoimmune antibodies.